# OWL-P53-INV1-TUMOR-SUPPRESSION — Invariant specification (v1)

**Document ID:** GH-OWL-P53-INV1-001  
**Status:** DRAFT (documentation-first; registry implementation **[I]** until wired)  
**Classification:** Design specification — research instrument posture per [GH-FS-001](../../FUNCTIONAL_SPECIFICATION.md). Not a diagnostic device claim.

## 1. Purpose

Define the **tumor-suppression pathway** composite invariant for GaiaHealth: **p53-pathway function** as a **C4 constraint** projected from **five simultaneous S4 measurement channels**, each with independent **M/T/I/A** epistemic tags, combined into a **coherence index** against a **master homeostasis phase** (denoted **Φ_master** in design docs).

**v1 scope:** **Ordinary invariant** — see [`MOTHER_INVARIANT_CCR_DECISION.md`](MOTHER_INVARIANT_CCR_DECISION.md). “Mother invariant” topology (other invariants projecting against OWL-P53) is **deferred to v2** pending three-cell architectural CCR.

## 2. Identifier

- **Invariant ID:** `OWL-P53-INV1-TUMOR-SUPPRESSION`
- **Version:** v1.0-doc (string stable for future registry rows)

## 3. Channels (S4)

| Channel | Measures (non-exhaustive) | Epistemic default at v1 |
|---------|---------------------------|-------------------------|
| Genetic | TP53 mutation / copy number / VUS handling | **(M)** when assay gold-standard; **(A)** for VUS per policy |
| Proteomic | MDM2, p21 (CDKN1A), PUMA, BAX, MDM4, etc. | **(M)** / **(T)** per assay |
| Cellular stress | ROS, IL-6, TNF-α, IL-1β, NAD+/NADH, etc. | **(T)** typical |
| Frequency | Acoustic / bioelectric waveform → FFT features | **(T)** — see [`FREQUENCY_BAND_POLICY.md`](FREQUENCY_BAND_POLICY.md); **no fixed Hz list in this file** |
| Imaging | CT / MRI / functional imaging where applicable | **(M)** when clinically sourced |

## 4. Composite gate (target semantics)

**Target constitutional structure** (implementation **[I]**):

- **All five** channels within declared bounds → composite **held** / pass.  
- **Drift in one** channel → **watch** / flagged drift (exact UX: Communion projection workbench — **[I]**).  
- **Drift in two or more** → **REFUSED** for uncontrolled multi-channel drift (policy detail in OQ synthetic tests).

## 5. Receipts

Each projection emits a **signed receipt** artifact (format **[I]** — align with existing games narrative / mesh receipt JSON). See **IQ/OQ/PQ** protocols.

## 6. References (canonical)

- Li–Fraumeni syndrome — clinical definition (attach in `evidence/references/`).  
- p53 pathway review literature — Vogelstein / Lane / Levine class (attach).  
- Elephant 20× TP53 — **related biology only** — [Abegglen et al., JAMA 2015](https://doi.org/10.1001/jama.2015.13134) — **not** a human PQ cohort requirement (see [`PQ_PROTOCOL.md`](PQ_PROTOCOL.md)).

## 7. Cross-links

- [`FREQUENCY_ADDENDUM.md`](FREQUENCY_ADDENDUM.md) — frequency channel detail and nested qualification.  
- [`SMALL_MOLECULE_INTEGRATION.md`](SMALL_MOLECULE_INTEGRATION.md) — drug programs as S4 interventions.  
- [`../../S4_C4_COMMUNION_UI_SPEC.md`](../../S4_C4_COMMUNION_UI_SPEC.md) — Communion UI design target.  
- Extended UI draft: [`../../../../../GaiaHealth/docs/UI_SPEC_S4C4_COMMUNION_V1.md`](../../../../../GaiaHealth/docs/UI_SPEC_S4C4_COMMUNION_V1.md) — **verify canonical merge plan**.
